Description

3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-1,4-Dihydro-8-Methoxy-7-(Octahydro-2-Oxo-6H-Pyrrolo[3,4-B]Pyridin-6-Yl)-4-Oxo- is a high-purity, advanced pharmaceutical intermediate with a complex heterocyclic structure. This compound is of significant commercial importance as a key building block in the synthesis of novel, potent antibacterial agents, specifically targeting DNA gyrase and topoisomerase IV. It is primarily required by pharmaceutical R&D laboratories and contract manufacturing organizations (CMOs) engaged in the development of next-generation fluoroquinolone antibiotics.

Application

• Active Pharmaceutical Ingredient (API) Synthesis: A critical intermediate in the multi-step synthesis of novel broad-spectrum antibacterial agents.
• Pharmaceutical Research & Development: Used in medicinal chemistry for structure-activity relationship (SAR) studies and the development of new quinolone-based drug candidates.
• Preclinical and Clinical Trial Material Manufacturing: Serves as a key starting material (KSM) or intermediate for producing batches under Good Manufacturing Practice (GMP) standards for regulatory submissions.
• Process Chemistry Optimization: Employed in scaling up and optimizing synthetic routes for cost-effective and robust commercial production of target APIs.
• Reference Standard: Used as a high-purity analytical standard for quality control and method validation in pharmaceutical analysis.

Basic Information

Product Name	3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-1,4-Dihydro-8-Methoxy-7-(Octahydro-2-Oxo-6H-Pyrrolo[3,4-B]Pyridin-6-Yl)-4-Oxo-
CAS No.	1620445-17-1
Molecular Formula	C21H22FN3O5
Molecular Weight	415.42 g/mol
Synonyms	1-Cyclopropyl-6-fluoro-8-methoxy-7-(octahydro-2-oxo-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-2-oxo-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid; Gepotidacin Intermediate; GSK2140944 Intermediate; Antibacterial Quinolone Intermediate; DNA Gyrase Inhibitor Intermediate; Topoisomerase IV Inhibitor Intermediate
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to strict quality management systems, ensuring batch-to-batch consistency and reliability for critical pharmaceutical applications. Quality is verified through comprehensive analytical testing including HPLC for purity and impurity profiling, NMR and MS for structural confirmation, and KF titration for moisture content. A detailed Certificate of Analysis (COA) is provided with each shipment, and we support customer audits and regulatory filings.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and must be kept under dry, inert conditions to maintain stability and purity. The storage area should be well-ventilated and separate from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Single Maximum Impurity	≤ 0.5%
Total Impurities	≤ 2.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.